To include your compound in the COVID-19 Resource Center, submit it here.
Data from 41 patients with solid tumors in the Phase Ib portion of an open-label, dose-escalation, U.S. Phase Ib/IIa trial
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury